
Now loading...
JM Financial recommends buying Aurobindo Pharma with a target price of Rs 1755, up from the current Rs 1173.7, due to expected growth from the flu season in the US and a slight margin expansion. Aurobindo Pharma reported a net profit of Rs 816.65 crore in the recent quarter and has strong promoter and institutional support.
Now loading...